Table 1 Conventional chemotherapy-based salvage regimens assessed in patients with R/R HL

MINE [25]

100

ORR = 75%

2-year survival rate

59%

ASHAP [22]

56

ORR = 70% (CR = 34%, PR = 36%)

OS, 5-year follow-up

41%

EFS, 5-year follow-up

36%

DHAP [20]

102

ORR = 88%,

(CR = 21%, PR = 67%)

NR

NR

ESHAP [23]

22

ORR = 73%

50-month follow-up

32% alive and disease-free

3-year estimates

OS = 35%

Disease-free = 27%

ESHAP [24]

82

ORR = 67%

(CR = 50%)

OS, 5-year follow-up

72.6%

PFS, 5-year follow-up

• Pts achieving CR = 78%

• Pts achieving PR = 16%

p < 0.01)

ICE [26]

65

ORR = 88%

(CR = 26%, PR = 58%)

OS, 43-month follow-up

83%

EFS, 43-month follow-up

68%

ICE [27]

R/R HL (n = 13)

non-HL (n = 62)

ORR = 89%

(CR = 29%, PR = 60%)

OS, 24-month follow-up

65% (all pts)

EFS, 24-month follow-up

42% (all pts)

ICE/aICE [35]

97

NR

OS, 51-month follow-up

80%

PFS, 51-month follow-up

70%

IVE [28]

51

ORR = 84%

(CR = 60%, good PR = 8%, PR = 16%)

NR

NR

IVOx [29]

34

ORR = 76% (CR = 32%)

OS, 5-year follow-up

74%

EFS, 5-year follow-up

63%

GVD pre- or post-ASCT [30]

94

ASCT-naïve pts. ORR = 61%

Prior-SCT pts. ORR = 75%

OS, 3.6-year follow-up

• SCT-naïve pts. median ORR = 61%

• Prior-SCT pts. ORR = 75%

EFS, 3.6-year follow-up

• SCT-naïve pts. median EFS not reached, 52% progression-free at 4 years

• Prior-SCT pts. median EFS duration 8.5 months

IGEV [31]

91

CR = 53.8%, PR = 27.5%

OS, 3-year follow-up

70.03%

PFS, 3-year follow-up

52.98%

BeGEV [34]

59

ORR = 83%

(CR = 73%, PR = 10%)

OS, 2-year follow-up

77.6%

PFS, 2-year follow-up

62.2%

GDP [32]

23

ORR = 69.5%

(CR = 17.3%, PR = 52.2%)

NR

NR

GemOx [33]

24

ORR = 71%

(CR = 38%, PR = 33%)

OS, 3-year follow-up

Median of 26 months

PFS, 3-year follow-up

Median of 14 months